Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLOB in Tibial Fracture
NCT04432389Phase 2Unknown
- Sponsor
- BioSenic
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Stem Cell Therapies
- Countries
- 7
01
Overview
A Phase 2 trial of allogeneic osteoblastic cells in tibial fracture, sponsored by BioSenic. Status: unknown.
02
Drugs
allogeneic osteoblastic cells
03
Conditions
tibial fracture
Beyond the preview
Go deeper on NCT04432389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432389.